Immune cells engineered to hunt two targets in brain cancer

NCT ID NCT05168423

Ongoing Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether specially engineered immune cells are safe and feasible for people with a recurring type of brain cancer called glioblastoma. The cells are designed to recognize and attack two specific proteins found on the cancer cells. The study involves 67 participants and focuses on side effects and manufacturing success, not yet on curing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells (CART-EGFR-IL13Ra2) that target two proteins on cancer cells
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is an early Phase 1 trial focused on safety, not yet on effectiveness. The treatment may cause serious side effects, and many experimental cell therapies fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR-AMPLIFIED RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classical glioblastoma glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.